Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.

Villacampa, Guillermo; Cresta Morgado, Pablo; Navarro, Victor; Viaplana, Cristina; Dienstmann, Rodrigo

Villacampa, Guillermo; Cresta Morgado, Pablo; Navarro, Victor; Viaplana, Cristina; Dienstmann, Rodrigo.

Afiliación

Villacampa G; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; The Institute of Cancer Research (ICR), London, United Kingdom.
Cresta Morgado P; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Prostate Cancer Translational Research Group, Barcelona, Spain.
Navarro V; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Viaplana C; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Dienstmann R; Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: rdienstmann@vhio.net.

Cancer Treat Rev ; 116: 102542, 2023 May.

Article en En | MEDLINE | ID: mdl-37003083

Asunto(s)

Neoplasias Pulmonares; Neoplasias; Humanos; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Antígeno B7-H1; Resultado del Tratamiento; Neoplasias/tratamiento farmacológico; Biomarcadores; Neoplasias Pulmonares/tratamiento farmacológico

Palabras clave

Duration of response; First-line; Immune checkpoint inhibitors; PD1/PD-L1; Surrogate endpoints

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares / Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Cancer Treat Rev Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google